04:44 AM EDT, 06/12/2024 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) and Mereo BioPharma Group ( MREO ) said late Tuesday a phase 2 study of setrusumab showed "ongoing and meaningful improvements" in the lumbar spine bone mineral density of patients with osteogenesis imperfecta.

The drug companies said the phase 2 portion of an ongoing phase 2/3 study showed that treatment with setrusumab reduced incidence of fractures by 67% in patients with osteogenesis imperfecta, a genetic bone disorder, with at least 14 months of follow-up.

The fracture rate excluded morphometric vertebral fractures as well as those of the fingers, toes, skull and face.

The reduction was associated with "clinically meaningful increases" in bone mineral density, the companies said.

Price: 43.00, Change: +1.60, Percent Change: +3.86